Kathleen Buchheit is a Rheumatology/Immunology physician affiliated with Brigham and Women's Hospital. OpenAlex indexes 127 publications with 5,813 citations (h-index 29).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
75 Francis St
Boston, MA 021156110
Telephone
617-732-9850Registry record last updated 22 Jun 2016.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year202514 payments$21,858openpaymentsdata.cms.gov ↗
- Eli Lilly and CompanyProgram year202511 payments$16,520openpaymentsdata.cms.gov ↗
- Regeneron Healthcare Solutions, Inc.Program year202512 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
53.3%Corticosteroid15.9%Budesonide-Formoterol Fumarate53%Fluticasone Propionate47%Part D<11 patientsLeukotriene Receptor Antagonist10.7%Montelukast Sodium100%Part D<11 patients+ 5 more classes in this area
Dermatology
46.7%Interleukin-4 Receptor alpha Antagonist46.7%Dupixent Syringe78%Dupixent Pen22%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2019–2026 per NIH RePORTER. The latest:
- Biomarkers predicting nasal polyp recurrence in aspirin-exacerbated respiratory disease
Brigham and Women'S Hospital
FY2026$223,750R21AI182809 - Biomarkers predicting nasal polyp recurrence in aspirin-exacerbated respiratory disease
Brigham and Women'S Hospital
FY2025$260,445R21AI182809 - The Role of IL-5 and Local Nasal Polyp Immunoglobulin Production in Aspirin-Exacerbated Respiratory Disease
Brigham and Women'S Hospital
FY2023$197,640K23AI139352
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Clinical efficacy and mechanisms of biologics for chronic rhinosinusitis with nasal polyps
Journal of Allergy and Clinical Immunology
2025 - Human intraepithelial mast cell differentiation and effector function are directed by TGF-β signaling
Journal of Clinical Investigation
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Paul Ridker, MD
Brigham and Women's Hospital
Scott Solomon, MD
Brigham and Women's Hospital
Dennis Selkoe, MD
Brigham and Women's Hospital
Marc Pfeffer, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”